This case study employs solution-focused brief therapy (SFBT) to alleviate depressive symptoms in an alcohol-dependent patient with comorbid personality disorder. Alcohol dependence and depression are frequent comorbid conditions in patients presenting for treatment. For some of these, personality disorders may further complicate treatment and even present a barrier to patients seeking or being offered treatment. In the case described, the patient only sought treatment after his gingivitis led to discovery of liver damage. In addition to SFBT, the patient was prescribed acamprosate to assist with abstinence from alcohol and fluoxetine for depression. Following three sessions of SFBT spaced at 1-month intervals, the patient reported maintaining abstinence from alcohol. His symptoms of depression as measured by Depression Anxiety Stress Scale reduced from severe to normal range, and he reported a reduction in the frequency and intensity of dark thoughts that had previously plagued him when sober. Outcomes were maintained 12 months following treatment.
AddisM. E.JacobsonN. S. (1996). Reasons for depression and the process and outcome of cognitive-behavioural psychotherapies. Journal of Consulting and Clinical Psychology, 64, 1417-1424.
2.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
3.
AndrewsG.SandersonK.SladeT.IssakidisC. (2000). Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization, 78, 446-454.
BaborT. F.Higgins-BiddleJ. C.SaundersJ. B.MonteiroM. G. (2001). The Alcohol Use Disorders Identification Test: Guidelines for use in primary care (2nd ed.). Geneva, Switzerland: WHO.
7.
BrownT. A.ChorpitaB. F.KorotitschW.BarlowD. H. (1997). Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behaviour Research and Therapy, 35, 79-89.
8.
CassanoP.FavaM. (2002). Depression and public health: An overview. Journal of Psychosomatic Research, 53, 849-857.
9.
ChaoJ.NestlerE. J. (2004). Molecular neurobiology of drug addiction. Annual Review of Medicine, 55, 113-132.
10.
ChastainG. (2006). Alcohol, neurotransmitter systems, and behavior. Journal of General Psychology, 133, 329-335.
11.
ChickJ.HowlettH.MorganM. Y.RitsonB. (2000). United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol and Alcoholism, 35, 176-187.
12.
CorcoranJ.PillaiV. (2007). A review of the research on solution-focused therapy. British Journal of Social Work, 10, 1-9.
13.
CraigheadW. E.HartA. B.CraigheadL. W.IlardiS. S. (2002). Psychosocial treatments for major depressive disorder. In NathanP. E.GormanJ. M. (Eds.), A guide to treatments that work, 2nd ed (pp 245-262). Oxford, UK: Oxford University Press.
14.
De ShazerS.IsebaertL. (2003). The Bruges model: A solution-focused approach to problem drinking. Journal of Family Psychotherapy, 14, 43-52.
15.
ElvinsR.GreenJ. (2008). The conceptualization and measurement of therapeutic alliance: An empirical review. Clinical Psychology Review, 28, 1167-1187. doi:org/10.1016/j.cpr.2008.04.002
16.
FergussonD. M.BodenJ. M.HorwoodL. J. (2009). Tests of causal links between alcohol abuse or dependence and major depression. Archives of General Psychiatry, 66, 260-266.
GingerichW. J.EisengartS. (2000). Solution focused brief therapy: A review of the outcome research. Family Process, 39, 477-498.
19.
GoldsteinB. I.DiamantourosA.SchafferA.NaranjoC. A. (2006). Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs, 66, 1229-1237.
20.
GreenbergP. E.KesslerR. C.BirnbaumH. G.LeongS. A.LoweS. W.BerglundP. A.Corey-LisleP. K. (2003). The economic burden of depression in the United States: How did it change between 1990 and 2000?Journal of Clinical Psychiatry, 64, 1465-1475.
21.
GutermanJ. T. (2006). Mastering the art of solution-focused counseling. Alexandria, VA: American Counseling Association.
22.
HatcherR. L. (2010). Alliance theory and measurement. In MuranJ. C.BarberJ. P. (Eds.), The therapeutic alliance: An evidence-based guide to practice. (pp 7-28). New York, NY: Guilford.
23.
HawthorneG.CheokF.GoldneyR.FisherL. (2003). The excess cost of depression in South Australia: A population based study. Australian New Zealand Journal of Psychiatry, 37, 363-373.
24.
HesseM. (2009). Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone: A systematic review of the published literature. BMC Psychiatry, 9, 6. doi:10.1186/1471-244X-9-6
25.
KanerE. F.DickinsonH. O.BeyerF. R.CampbellF.SchlesingerC.HeatherN.. . . PienaarE. D. (2007). Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database of Systematic Reviews, 2, CD004148.
26.
KapasovaZ.SzumlinskiK. K. (2008). Strain differences in alcohol-induced neurochemical plasticity: A role for accumbens glutamate in alcohol intake. Alcoholism: Clinical & Experimental Research, 32, 617-631.
27.
KimJ. S. (2008). Examining the effectiveness of solution-focused brief therapy: A meta-analysis. Research on Social Work Practice, 18, 107-116.
28.
KimJ. S.FranklinC. (2009). Solution-focused brief therapy in schools: A review of the outcome literature. Children and Youth Services Review, 31, 464-470.
29.
KnektP.LindforsO. (2004). A randomized trial of the effect of four forms of psychotherapy on depressive and anxiety disorders: Design, methods and results on the effectiveness of short-term psychodynamic psychotherapy and solution-focused therapy during a one-year follow-up. Studies in Social Security and Health, 77. Helsinki, Finland: The Social Insurance Institution. HYPERLINK “http://www.ktl.fi/tto/hps/pdf/effectiveness.pdf”www.ktl.fi/tto/hps/pdf/effectiveness.pdf
30.
KoobG. F.Le MoalM. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24, 97-129.
31.
LohE. W.BallD. (2000). Role of the GABA (A) beta2, GABA (A) alpha6, GABA (A) alpha1 and GABA (A) gamma2 receptor subunit genes cluster in drug responses and the development of alcohol dependence. Neurochemistry International, 37, 413-423.
32.
LovibondS. H.LovibondP. F. (1995). Manual for the Depression Anxiety Stress Scales (2nd ed.). Sydney, Australia: Psychology Foundation.
33.
ManjiH. K.MooreG. J.RajkowskaG.ChenG. (2000). Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry, 5, 578-593.
34.
MeierP. S.BarrowcloughC.DonmallM. C. (2005). The role of the therapeutic alliance in the treatment of substance misuse: A critical review of the literature. Addiction, 100, 304-316. doi:10.1111/j.1360-0443.2004.00935.x
35.
MillerW. R.WilbourneP. L. (2002). Mesa Grande: A methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction, 97, 265-277.
36.
MoyerA.FinneyJ. W.SwearingenC. E.VergunP. (2002). Brief interventions for alcohol problems: A meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction, 97, 279-292.
37.
MyrickH.AntonR. (2004). Recent advances in the pharmacotherapy of alcoholism. Current Psychiatry Reports, 6, 332-338.
38.
MyrickH.CluverJ.SwavelyS.PetersH. (2004). Diagnosis and treatment of co-occurring affective disorders and substance use disorders. Psychiatric Clinics of North America, 27, 649-659.
39.
NemeroffC. B.SchatzbergA. F. (2002). Pharmacological treatments for unipolar depression. In NathanP. E.GormanJ. M. (Eds.), A guide to treatments that work (2nd ed., pp. 229-243). Oxford, UK: Oxford University Press.
40.
O’BrienC. P. (2005). Anticraving medications for relapse prevention: A possible new class of psychoactive medications. American Journal of Psychiatry, 162, 1423-1431.
41.
ParsianA.ZhangZ. H. (1999). Human chromosomes 11p15 and 4p12 and alcohol dependence: Possible association with the GABRB1 gene. American Journal of Medical Genetics, 88, 533-538.
42.
PichotT. (2007). Looking beyond depression. In NelsonT. S.ThomasF. N. (Eds.), Handbook of solution-focused brief therapy: Clinical applications (pp. 117-124). New York, NY: Haworth.
43.
RapaportM. H.ClaryC.FayyadR.EndicottJ. (2005). Quality-of-life impairment in depressive and anxiety disorders. American Journal of Psychiatry, 162, 1171-1178.
44.
RectorN. A.BagbyR. M.SegalZ. V.JoffeR. T.LevittA. (2000). Self-criticism and dependency in depressed patients treated with cognitive therapy or pharmacotherapy. Cognitive Therapy and Research, 24, 571-584.
45.
SchuckitM.TapertS. (2004). Alcohol. In GalanterM.KleberH. (Eds.), Textbook of substance abuse treatment (pp. 151-166). Washington, DC: American Psychiatric Publishing.
46.
SheaM. T.PilkonisP. A.BeckhamE.CollinsJ. F.ElkinI.SotskyS. M.DochertyJ. P. (1990). Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry, 147, 711-718.
47.
SheehanD. V.LecrubierY.SheehanK. H.AmorimP.JanavsJ.WeillerE.. . . DunbarG. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl. 20), 22-33.
48.
SmockS. A.TrepperT. S.WetchlerJ. L.McCollumE. E.RayR.PierceK. (2008). Solution-focused group therapy for level 1 substance abusers. Journal of Marital & Family Therapy, 34, 107-120.
49.
SotskyS. M.GlassD. R.SheaM. T.PilkonisP. A.CollinsJ. F.ElkinI.. . . OliveriM. E. (1991). Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry, 148, 997-1008.
50.
SpilsburyG. (2009). [omit (2008)]. Motivational interviewing: Enhancing the process of change. In LattN.ConigraveKSaundersJ. B.MarshallE. J.NuttD. (Eds.), Addiction medicine: Oxford specialist handbooks. (pp. 62-4). Oxford, UK: Oxford University Press.
51.
StahlS. M. (2000). Essential psychopharmacology of depression and bipolar disorder. New York, NY: Cambridge University Press.
52.
StarostaA. N.LeemanR. F.VolpicelliJ. R. (2006). The BRENDA model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. Journal of Psychiatric Practice, 12, 80-89.
53.
SzumlinskiK. K.DiabM. E.FriedmanR.HenzeL. M.LominacK. D.BowersM. S. (2007). Accumbens neurochemical adaptations produced by binge-like alcohol consumption. Psychopharmacology, 190, 415-431.
54.
TallmanK.BohartA. C. (1999). The client as common factor: Clients as self-healers. In HubbleM. A.DuncanB. L.MillerS. D. (Eds.), The heart and soul of change: What works in therapy (pp. 91-132). Washington, DC: American Psychological Association.
55.
TeessonM.HallW.SladeT.MillsK.GroveR.MewtonL.. . . HaberP. (2010). Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: Findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction, 105, 2085-2094. doi:10.1111/j.1360-0443.2010.03096.x
56.
ThaseM. E. (2001). Neuroimaging profiles and the differential therapies of depression. Archives of General Psychiatry, 58, 651-652.
57.
WeissR. D.KueppenbenderK. D. (2006). Combining psychosocial treatment with pharmacotherapy for alcohol dependence. Journal of Clinical Psychopharmacology, 26, S37-S42.
58.
WHO Brief Intervention Study Group. (1996). A cross-national trial of brief interventions with heavy drinkers. American Journal of Public Health, 86, 948-955.
59.
ZuroffD. C.BlattS. J. (2006). The therapeutic relationship in the brief treatment of depression: Contributions to clinical improvement and enhanced adaptive capacities. Journal of Consulting and Clinical Psychology, 74, 130-140.
